Artelo Biosciences (ARTL) said Monday that new preclinical data showed its drug candidate ART12.11 demonstrated antidepressant-like activity and cognitive benefits in a stress-induced depression model in rats.
The company said a 28-day regimen reversed depressive behaviors and improved cognitive function, performing comparably to the selective serotonin reuptake inhibitor Sertraline in behavioral measures.
ART12.11 also restored spatial and short-term memory deficits without negatively impacting social memory, according to the company.
The company's shares were up 179% in recent premarket activity on Monday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。